Sacred and magic – the past and the present of hallucinogenic mushrooms containing psilocybin and its derivatives

• Authors: Joanna Helena SZELEGIENIEC , Szymon Stanisław NOWAK

Title variants

PL

Święte i magiczne – pradawne i obecne gatunki grzybów halucynogennych zawierających psylocybinę i jej pochodne

• Languages of publication: PL

Abstracts

EN

Mushrooms containing hallucinogenic indole compounds are one of the sources of psychoactive substances which are found in nature. These species contain indole derivatives such as for example psilocybin, a naturally occurring hallucinogen. The potential of these compunds for occasioning altered states of consciousness has probably been known by human kind from the very beginning, which is indicated by the ancient findings. The aim of this article is to address the issue of using hallucinogenic mushrooms in purpose of altering consciousness. This work presents a brief report of marks for the ancient use of hallucinogenic mushrooms and other hallucinogens, and discusses the matter of religious experiences facilitated by the use of hallucinogenic indole derivatives. Finally, the controversies over the hallucinogenic substances are taken under consideration.

Keywords

EN

"altered states of consciousness"; "entheogen; "hallucinations"; "shamanism"; hallucinogenic mushrooms"; psilocybin"

Discipline

• BOTANY: BOTANY

• Publisher: ZOZ Ośrodek UMEA SHINODA-KURACEJO
• Journal: Medicina Internacia Revuo
• Year: 2016
• Volume: 27
• Issue: 106
• Pages: 40-46

Contributors

author

Joanna Helena SZELEGIENIEC

• Zakład Ontologii, Instytut Filozofii, Wydział Filozoficzny, Uniwersytet Jagielloński, Kraków

author

Szymon Stanisław NOWAK

• Zakład Ontologii, Instytut Filozofii, Wydział Filozoficzny, Uniwersytet Jagielloński, Kraków

References

• 1. Revonsuo, A.; Kallio, S.; Sikka, P.;. Philos. Psychol. 2009, 22(2), 187-204.
• 2. Ustinova, J.; w: Cardeña, E.; Winkelman, M. (red.); Praeger Publishers, Santa Barbara, CADenver, CO-Oxford, 2011, 45-72.
• 3. Presti, D. E.; W: Cardeña, E.; Winkelman, M., (red.); Praeger Publishers, 2011, 21-41.
• 4. Allen, J. W.; Arthur, J.; W: Metzner, R.; Darling, D.C., (red.); Park Street Press, 2005, 49-68.
• 5. Blom, J. D. (red.); Springer, New York-DordrechtHeidelberg-London, 2010.
• 6. Gartz, J.; LIS Publications, Los Angeles, CA, 1996.
• 7. Guzmán, G.; Allen, J. W.; Gartz, J.;. Ann. Mus. civ. Rovereto. 1998, 14, 189-280.
• 8. Passie, T.; Seifert, J.; Schneider, U.; Emrich, H. M.;. Addict. Biol. 2002, 7(4), 357-364.
• 9. Nichols, D. E.;. Pharmacol. Ther. 2004, 101(2), 131181.
• 10. Nichols, D. E.; Chemel, B. R.;. W: McNamara, P., (red.); Praeger Publishers, Wesport, CT-London, 2006, 1-33.
• 11. Frecska, E.; Luna, L.E.;. Neuropsychopharmacol. Hung. 2006, 8(4), 189-200.
• 12. Winkelman, M.; Praeger Publishers, Santa Barbara, CA, 2010.
• 13. Winkelman, M.; W: Walter, M. N.; Neumann Fridman, E. J., (red.); ABC Clio, Oxford, 2004, 6170.
• 14. Whitley, D. S.; W: Walter, M. N.; Neumann Fridman, E. J., (red.); ABC Clio, Oxford, 2004, 1620.
• 15. Winkelman, M.;. Zygon. 39(1), 193-217.
• 16. Metzner, R.;. J. Psychoactive Drugs. 1998, 30(4), 333-341.
• 17. Guerra-Doce, E.;. Time and Mind: J. Archaeol. Conscious. Cultur. 2015, 8(1), 91-112.
• 18. Tayade, S. K.; Dhale, D. A.; Patil, D. A.;. J. Ethnobiol. Traditional Med. 2013, 118, 340-351.
• 19. Schultes, R. E.;. Heffter Rev. Psychedelic Res. 1998, 1, 1-7.
• 20. Terry, M.; Steelman, K. L.; Guilderson, T.; Dering, P.; Rowe, M. W.;. J. Archaeol. Sci. 2006, 33(7), 10171021.
• 21. Samorini, G.;. Integration. 1992, 2/3, 69-78.
• 22. Guzmán, G.;. Acta Bot. Mex. 2012, 100, 79-106.
• 23. Akers, B. P.; Ruiz, J. F.; Piper, A.; Ruck, C. A.;. Econ. Bot. 2011, 65(2), 121-128.
• 24. Guerra-Doce, E.;. J. Archaeol. Method Theory. 2015, 22, 751-782.
• 25. Ott, J.;. Natural Products Co., Kennewick, WA, 1996.
• 26. Griffiths, R. R.; Johnson, M. W.; Richards, W. A.; Richards, B. D.; McCann, U.; Jesse, R.;. Psychopharmacology. 2011, 218(4), 649-665.
• 27. Doblin, R.;. J. Transpersonal Psychol. 1991, 23(1), 1-28.
• 28. MacLean, K. A.; Johnson, M. W.; Leoutsakos, J.-M. S.; Griffiths, R. R.;. J. Sci. Study Relig. 2012, 51(4), 721-737.
• 29. Grob, C. S.; Danforth, A. L.; Chopra, G. S.; Hagerty, M.; McKay, C. R.; Halperstadt, A. L. ; et al.;. Arch Gen Psychiatry. 2011, 68(1), 71-78.
• 30. http://www.clinicaltrials.gov/ct2/show/study/ NCT00465595term=Psilocybin&rank=5.
• 31. Moreno, F.; Wiegand, C. B.; Taitano, E. K.; Delgado, P. L.;. J. Clin. Psychiatry. 2006, 67(11),
• 32. Vollenweider, F. X.; Kometer, M.;. Nat. Rev. Neurosci. 2010, 11, 642-651.
• 33. Carhart-Harris, R. L.; Leech, R.; Williams, T. M.; Erritzoe, D.; Abbasi, N.; Bargiotas, T.; et al.;. Br. J. Psychiatry. 2012, 200, 238-244.
• 34. Spilane, J.; McAllister, W. B.;. Drug Alcohol. Depend. 2003, 70(3 Supp), 5-12.
• 35. James, W.; Wydawnictwo Nomos, Kraków, 2011. Eliade, M.; Wydawnictwo Aletheia,
• Warszawa, 2011.
• 36. Rostkowska-Nadolska, B.; Machoń, Z.;. Toksykologia. 2009, 65, 2, 138-146.

• Document Type: review